Literature DB >> 30851359

Grade-specific diagnostic and prognostic biomarkers in breast cancer.

V S P K Sankara Aditya Jayanthi1, Asim Bikas Das2, Urmila Saxena3.   

Abstract

An integrative approach is presented to identify grade-specific biomarkers for breast cancer. Grade-specific molecular interaction networks were constructed with differentially expressed genes (DEGs) of cancer grade 1, 2, and 3. We observed that the molecular network of grade3 is predominantly associated with cancer-specific processes. Among the top ten connected DEGs in the grade3, the increase in the expression of UBE2C and CCNB2 genes was statistically significant across different grades. Along with UBE2C and CCNB2 genes, the CDK1, KIF2C, NDC80, and CCNB2 genes are also profoundly expressed in different grades and reduce the patient's survival. Gene set enrichment analysis of these six genes reconfirms their role in metastatic phenotype. Moreover, the coexpression network shows a strong association of these six genes promotes cancer specific biological processes and possibly drives cancer from lower to a higher grade. Collectively the identified genes can act as potential biomarkers for breast cancer diagnosis and prognosis.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Diagnostic markers; Grade-specific network; Prognosis; Survival analysis

Mesh:

Substances:

Year:  2019        PMID: 30851359     DOI: 10.1016/j.ygeno.2019.03.001

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  9 in total

1.  A Translational Pipeline for Overall Survival Prediction of Breast Cancer Patients by Decision-Level Integration of Multi-Omics Data.

Authors:  Jonathan Mitchel; Kevin Chatlin; Li Tong; May D Wang
Journal:  Proceedings (IEEE Int Conf Bioinformatics Biomed)       Date:  2020-02-06

2.  Game-theoretic link relevance indexing on genome-wide expression dataset identifies putative salient genes with potential etiological and diapeutics role in colorectal cancer.

Authors:  Vishwa Jyoti Baruah; Papori Neog Bora; Bhaswati Sarmah; Priyakshi Mahanta; Ankumon Sarmah; Stefano Moretti; Rajnish Kumar; Surajit Borkotokey
Journal:  Sci Rep       Date:  2022-08-04       Impact factor: 4.996

3.  PCMT1 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltrates in Breast Cancer.

Authors:  Jufang Guo; Xuelian Du; Chaolin Li
Journal:  Biomed Res Int       Date:  2022-04-30       Impact factor: 3.246

Review 4.  Why Great Mitotic Inhibitors Make Poor Cancer Drugs.

Authors:  Victoria C Yan; Hannah E Butterfield; Anton H Poral; Matthew J Yan; Kristine L Yang; Cong-Dat Pham; Florian L Muller
Journal:  Trends Cancer       Date:  2020-06-11

5.  Sp1 contributes to radioresistance of cervical cancer through targeting G2/M cell cycle checkpoint CDK1.

Authors:  Yuan-Run Deng; Xiao-Jing Chen; Wei Chen; Lan-Fang Wu; Hui-Ping Jiang; Dan Lin; Li-Jing Wang; Wei Wang; Sui-Qun Guo
Journal:  Cancer Manag Res       Date:  2019-06-28       Impact factor: 3.989

6.  A Deep Learning-Based Framework for Supporting Clinical Diagnosis of Glioblastoma Subtypes.

Authors:  Sana Munquad; Tapas Si; Saurav Mallik; Asim Bikas Das; Zhongming Zhao
Journal:  Front Genet       Date:  2022-03-28       Impact factor: 4.599

7.  Cyclin genes as potential novel prognostic biomarkers and therapeutic targets in breast cancer.

Authors:  Nian-Qiu Liu; Wei-Han Cao; Xing Wang; Junyao Chen; Jianyun Nie
Journal:  Oncol Lett       Date:  2022-09-05       Impact factor: 3.111

8.  Identification of Hub Genes Using Co-Expression Network Analysis in Breast Cancer as a Tool to Predict Different Stages.

Authors:  Yun Fu; Qu-Zhi Zhou; Xiao-Lei Zhang; Zhen-Zhen Wang; Peng Wang
Journal:  Med Sci Monit       Date:  2019-11-23

9.  Gene signatures and prognostic analyses of the Tob/BTG pituitary tumor-transforming gene (PTTG) family in clinical breast cancer patients.

Authors:  Chung-Che Wu; Titus Ime Ekanem; Nam Nhut Phan; Do Thi Thuy Loan; Sz-Ying Hou; Kuen-Haur Lee; Chih-Yang Wang
Journal:  Int J Med Sci       Date:  2020-10-22       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.